Patents Assigned to SILVERBACK THERAPEUTICS, INC.
  • Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof
    Patent number: 11541126
    Abstract: The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: January 3, 2023
    Assignee: SILVERBACK THERAPEUTICS, INC.
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Philip Tan, Peter A. Thompson, Sean W. Smith, Brenda Stevens
  • Nectin-4 antibody conjugates and uses thereof
    Patent number: 11179473
    Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: November 23, 2021
    Assignee: Silverback Therapeutics, Inc.
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
  • Formulations of Benzazepine Conjugates and Uses Thereof
    Publication number: 20210077632
    Abstract: Aqueous formulations comprising conjugates that comprise a compound comprising benzazepine or a benzazepine-like structure conjugated to a polypeptide are provided, as well as methods of treatment using the aqueous formulations. Lyophilized compositions comprising the conjugates that comprise a compound comprising benzazepine or a benzazepine-like structure conjugated to a polypeptide are also provided.
    Type: Application
    Filed: August 14, 2020
    Publication date: March 18, 2021
    Applicant: Silverback Therapeutics, Inc.
    Inventors: Sean Wesley Smith, Sateesh Natarajan
  • Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
    Publication number: 20200113912
    Abstract: Methods and conjugates are disclosed for alleviating toxicity(ies) associated with administration of immune-stimulatory conjugates, and in particular for alleviating toxicity(ies) associated with intravenous administration of such conjugates.
    Type: Application
    Filed: September 11, 2019
    Publication date: April 16, 2020
    Applicant: Silverback Therapeutics, Inc.
    Inventors: Valerie Odegard, Peter Baum, Sean Wesley Smith, Craig Alan Coburn, Peter Armstrong Thompson
  • Benzazepine compounds, conjugates, and uses thereof
    Patent number: 10519131
    Abstract: Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 31, 2019
    Assignee: SILVERBACK THERAPEUTICS, INC.
    Inventors: Craig Alan Coburn, Peter Robert Baum, Sean Wesley Smith
  • Benzazepine compounds, conjugates, and uses thereof
    Patent number: 10442790
    Abstract: Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 15, 2019
    Assignee: Silverback Therapeutics, Inc.
    Inventors: Craig Alan Coburn, Peter Robert Baum, Sean Wesley Smith
  • Benzazepine compounds, conjugates, and uses thereof
    Patent number: 10428045
    Abstract: Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 1, 2019
    Assignee: Silverback Therapeutics, Inc.
    Inventors: Craig Alan Coburn, Peter Robert Baum, Sean Wesley Smith
  • Benzazepine compounds, conjugates, and uses thereof
    Patent number: 10239862
    Abstract: Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 26, 2019
    Assignee: SILVERBACK THERAPEUTICS, INC.
    Inventors: Craig Alan Coburn, Peter Robert Baum, Sean Wesley Smith